# Hypercholesterolemia Impairs the Expression of Angiogenic MicroRNAs in Extracellular Vesicles Within Ischemic Skeletal Muscles

**Authors:** Nozha Raguema, Sylvie Dussault, Kevin Sawaya, Michel Desjarlais, Eric Boilard, Sylvain Chemtob, Alain Rivard

PMC · DOI: 10.3390/ncrna12010003 · Non-Coding RNA · 2026-01-26

## TL;DR

High cholesterol reduces specific microRNAs in muscle vesicles that help form new blood vessels, worsening blood flow in severe leg artery disease.

## Contribution

Identifies specific angiogenic microRNAs impaired by hypercholesterolemia in extracellular vesicles and their potential for therapeutic targeting.

## Key findings

- Hypercholesterolemia reduces pro-angiogenic microRNAs in large and small extracellular vesicles.
- Overexpression of specific microRNAs enhances angiogenic capacity of extracellular vesicles in vitro.
- Impaired microRNAs affect key signaling pathways like HIF-1 and MAPK, crucial for neovascularization.

## Abstract

Background/Objectives: In severe peripheral artery disease (PAD) with limb ischemia, hypercholesterolemia (HC) is associated with impaired neovascularization. Extracellular vesicles (EVs) are present within ischemic muscles, and they contain microRNAs (miRs) involved in several biological functions, including angiogenesis and neovascularization. Methods: We used a mouse model of PAD and compared the response to hindlimb ischemia in hypercholesterolemic ApoE−/− vs. normocholesterolemic mice. Next-generation sequencing (NGS) was used to perform full miR expression profiling in ischemic skeletal muscles and in EVs of varying sizes—large EVs (lEVs) and small EVs (sEVs)—within these muscles. Results: We identified several miRs with potential pro-angiogenic effects (angiomiRs) that are reduced by HC in lEVs (Let-7b-5p, miR-151-3p, Let-7c-5p) or sEVs (miR-21a-5p, miR-196b-5p, miR-340-5p). As proof of principle, we showed that the overexpression of Let-7b-5p in lEVs, or miR-21a-5p in sEVs, can significantly increase the angiogenic capacity of these EVs in vitro. HC also impaired the enrichment of specific angiomiRs in lEVs (miR-100-5p), sEVs (miR-142a-3p), or in both lEVs and sEVs (miR-146b-5p). In silico approaches, including the prediction of miR targets, pathway unions, and gene unions, identified the resulting predictive effects of HC-modulated miRs in EVs on processes with key roles in the modulation of angiogenesis and neovascularization, such as the regulation of the actin cytoskeleton and focal adhesion and the HIF-1, MAPK, AMPK, and PI3K-Akt signaling pathways. Conclusions: Our results constitute an important first step towards the identification of specific miRs that could be targeted to improve EV angiogenic function in hypercholesterolemic conditions and reduce tissue ischemia in patients with severe PAD.

## Linked entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348]
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Mir615 (microRNA 615) [NCBI Gene 751557] {aka Mir, Mirn615, mir-615, mmu-mir-615}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, Hipk2 (homeodomain interacting protein kinase 2) [NCBI Gene 15258] {aka 1110014O20Rik, B230339E18Rik, Stank}, Ago1 (argonaute RISC catalytic subunit 1) [NCBI Gene 236511] {aka Eif2c1}, Tgfbr1 (transforming growth factor, beta receptor I) [NCBI Gene 21812] {aka ALK5, Alk-5, ESK2, TGFR-1, TbetaR-I, TbetaRI}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Pten (phosphatase and tensin homolog) [NCBI Gene 19211] {aka 2310035O07Rik, A130070J02Rik, B430203M17Rik, MMAC1, PTENbeta, TEP1}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Ago2 (argonaute RISC catalytic subunit 2) [NCBI Gene 239528] {aka 1110029L17Rik, 2310051F07Rik, Eif2c2, Gerp95, Gm10365, mKIAA4215}, Traf6 (TNF receptor-associated factor 6) [NCBI Gene 22034] {aka 2310003F17Rik, C630032O20Rik}, Cav1 (caveolin 1, caveolae protein) [NCBI Gene 12389] {aka Cav, Cav-1}, Smad2 (SMAD family member 2) [NCBI Gene 17126] {aka 7120426M23Rik, Madh2, Madr2, Smad-2, mMad2}, Snai2 (snail family zinc finger 2) [NCBI Gene 20583] {aka Slug, Slugh, Snail2}, Xrn1 (5'-3' exoribonuclease 1) [NCBI Gene 24127] {aka Dhm2, exo, mXrn1}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Cdkn1b (cyclin dependent kinase inhibitor 1B) [NCBI Gene 12576] {aka Kip1, p27, p27Kip1}, Ing5 (inhibitor of growth family, member 5) [NCBI Gene 66262] {aka 1700001C14Rik, 1700027H23Rik, 1810018M11Rik}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Vhl (von Hippel-Lindau tumor suppressor) [NCBI Gene 22346] {aka Vhlh, pVHL}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, Hnrnpa2b1 (heterogeneous nuclear ribonucleoprotein A2/B1) [NCBI Gene 53379] {aka 9130414A06Rik, Hnrpa2, Hnrpa2b1, hnrnp-A}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060]
- **Diseases:** injury to (MESH:D014947), inflammation (MESH:D007249), ischemic muscle (MESH:D019042), atherosclerosis (MESH:D050197), limb loss (MESH:D001259), pain (MESH:D010146), Ischemic (MESH:D002545), ischemic vascular disease (MESH:D014652), diabetic retinopathy (MESH:D003930), cancer (MESH:D009369), multiple myeloma (MESH:D009101), cardiovascular diseases (MESH:D002318), ulcers (MESH:D014456), vascular obstruction (MESH:D057772), hypercholesterolemic (MESH:D006938), HC (MESH:D006937), hypoxic (MESH:D002534), PAD (MESH:D058729), muscle pain (MESH:D063806), spinal cord injury (MESH:D013119), gangrene (MESH:D005734), necrosis (MESH:D009336), Ischemia (MESH:D007511), claudication (MESH:D007383), hypoxia (MESH:D000860), ischemic tissue injury (MESH:D017695)
- **Chemicals:** Be (MESH:D001608), NO (MESH:D009614), DMEM (-), oxygen (MESH:D010100), penicillin (MESH:D010406), hydrocortisone (MESH:D006854), D-PBS (MESH:C012939), streptomycin (MESH:D013307), CO2 (MESH:D002245), M200 (MESH:C516631), lipid (MESH:D008055), isoflurane (MESH:D007530), heparin (MESH:D006493)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922120/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12922120/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922120/full.md

---
Source: https://tomesphere.com/paper/PMC12922120